Tag Archives: Health Care

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

New Report Suggests RDP Does Not Increase Healthcare Expenditures

health care, medicine

A new paper by the Geneva Network suggests that increasing the period of regulatory data protection (RDP) for biologic medicines would not increase expenditures for medicines. As countries navigate the final negotiations in the Trans-Pacific Partnership, the U.S. and Japan have advocated for increased regulatory data protection for biologic medicines by other TPP countries. In the U.S. biologics enjoy 12 years of data exclusivity; the only TPP countries, aside from the U.S, offering more than Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

72263479

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Building a new franchise in a therapeutic from scratch poses a host of challenges, from whether to take the risk of entering a new area at all to whether and how to partner strategically with another company. It’s a challenge for both the biggest biopharma companies and emerging biotechs to evaluate how and when to enter new therapeutic areas and to try to ensure that their efforts will not only help patients in need but Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

BIO Official Blogger

Everyday our BIO Official Bloggers, writers who are on top of the biotechnology beat, release statements about their experience at the BIO International Convention. Here is what they want to share with you today: Scrip Intelligence By Lisa LaMotta Roche’s strong deal-making position is at least partly due to its acquisition of Genentech, but partnering head Sophie Kornowski-Bonnet explained that the firm is more interested in looking for drugs than bolt-on companies. Read more…   Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,